Media coverage about Syndax Pharmaceuticals (NASDAQ:SNDX) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.6226642807477 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

SNDX has been the subject of several recent research reports. Zacks Investment Research lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 11th. Citigroup set a $20.00 target price on shares of Syndax Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 11th. Nomura cut their target price on shares of Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 11th. Oppenheimer increased their target price on shares of Syndax Pharmaceuticals to $29.00 and gave the company an “outperform” rating in a research note on Friday, August 11th. Finally, Instinet reissued a “buy” rating and set a $22.00 target price (down from $27.00) on shares of Syndax Pharmaceuticals in a research note on Monday, August 14th. Two analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.13.

Shares of Syndax Pharmaceuticals (NASDAQ SNDX) traded down $0.16 during trading hours on Wednesday, hitting $8.12. 1,196,300 shares of the company traded hands, compared to its average volume of 157,607. Syndax Pharmaceuticals has a fifty-two week low of $6.31 and a fifty-two week high of $15.70.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.68) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.12. The business had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.30 million. Syndax Pharmaceuticals had a negative net margin of 4,304.34% and a negative return on equity of 57.90%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.84) EPS. research analysts forecast that Syndax Pharmaceuticals will post -3.03 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/29/syndax-pharmaceuticals-sndx-receives-coverage-optimism-rating-of-0-12.html.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Insider Buying and Selling by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.